IP Library Granted Patent US 8,101,653
Granted Patent B2
US 8,101,653 · App. 10/763,393 · Granted Jan 24, 2012

Therapeutic compositions

Assignee: BTG International Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,101,653
App. No.
10/763,393
Granted
Jan 24, 2012
Kind
B2
Abstract

Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

Claims (6)

1. A method of treating a patient for memory loss associated with aging comprising administering to that patient a therapeutically effective amount of at least one of D-β-hydroxybutyric acid, acetoacetate, or a metabolic precursor or physiologically acceptable salt of D-β-hydroxybutyric acid or acetoacetate, such as to elevate the patient's blood levels of ketone bodies, defined as the sum total of D-β-hydroxybutyric acid and acetoacetate, to a therapeutic level effective to treat the disorder, wherein the patient's blood level is elevated to from 0.3 mM to 20 mM, wherein the metabolic precursor is selected from the group consisting of:

(i) oligomers of D-β-hydroxybutyric acid,

(ii) esters of D-β-hydroxybutyric acid or its oligomers with monohydric, dihydric or trihydric alcohols or with acetoacetate,

(iii) esters of acetoacetate with monohydric, dihydric or trihydric alcohols,

wherein the monohydric, dihydric or trihydric alcohols in (ii) and (iii) are selected from the group C1-C4 alkyl alcohols, (R)-1,3-butandiol and glycerol.

2. A method as claimed in claim 1 wherein the memory loss associated with ageing is caused by Alzheimer's disease or an inability to metabolise glucose.

Assignments (1)
CHANGE OF ADDRESS CERTIFICATE Recorded Jun 3, 2014
From: BTG INTERNATIONAL LIMITED
To: BTG INTERNATIONAL LIMITED
Reel/Frame 033080/0853 →
Continuity (7)
Continuation 10408667 · Apr 8, 2003
Continuation 10153873 · May 24, 2002
Continuation 09843694 · Apr 30, 2001
Continuation 09397100 · Sep 16, 1999
Continuation In Part PCTUS9805072 · Mar 17, 1998
Provisional Application 60040858 · Mar 17, 1997
Related Publication 20040266872A1 · Dec 30, 2004